SG11201901989VA - Factor viia glycoforms - Google Patents
Factor viia glycoformsInfo
- Publication number
- SG11201901989VA SG11201901989VA SG11201901989VA SG11201901989VA SG11201901989VA SG 11201901989V A SG11201901989V A SG 11201901989VA SG 11201901989V A SG11201901989V A SG 11201901989VA SG 11201901989V A SG11201901989V A SG 11201901989VA SG 11201901989V A SG11201901989V A SG 11201901989VA
- Authority
- SG
- Singapore
- Prior art keywords
- man
- fuc
- international
- rule
- gicnac
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 011101011M 01 110 1 01011111110101111101010111B 1111 OEN Organization (10) International Publication Number International Bureau (43) International Publication Date ......0\"\" WO 2018/052827 Al 22 March 2018 (22.03.2018) WIP0 I PCT (51) International Patent Classification: (74) Agent: HANSEN, Christine M. et al.; Buchanan Inger- C07K 14/745 (2006.01) A61K 38/17 (2006.01) soli & Rooney PC, P.O. Box 1404, Alexandria, Virginia C07K 14/435 (2006.01) C12N 9/64 (2006.01) 22313-1404 (US). A61K 38/36 (2006.01) C12N 5/10 (2006.01) A61K 38/48 (2006.01) A61P 7/04 (2006.01) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, PCT/US2017/050887 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 11 September 2017 (11.09.2017) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (25) Filing Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (30) Priority Data: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/393,930 13 September 2016 (13.09.2016) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: BAYER HEALTHCARE LLC [US/US]; 100 kind of regional protection available): ARIPO (BW, GH, Bayer Boulevard, Whippany, New Jersey 07981 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventor: FELDMAN, Richard Ira; 100 Pomona Avenue, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — El Cerrito, California 94530 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) Title: FACTOR VIIA GLYCOFORMS = — FIG. 3 GLYCAN NADER FORMULA EXRUCTURE EMPLARY ST (GIcNAc)4(Man)3(Gai)2(Po = II (C1cNk)Man)3(Gag(Fuc) = III PcNA46(Mar)3(Fuc) = 1 \ / (GIcNAc)5(1,103(G81)3(PLE) = = = V (GcNA06(GaWan)tuc) = vi (acw 4 (man) 3 (GdxFuo = VI (GcNAc)5(Man)3(Fuc) — AI (GIcNAc)5(Man)3(Gal) 11 I X (Man)5(GIGNA43(G1)(Fuc) Ba IN N X (dcNAc)3(Man)3(GA)(Fuc) LEGEND GC 0 = GALACTOSE (Gal) N 11 in © XI (GNNAck(Man)3(G4I) O a z N- :, — TYLOALACTOSAMINE (GIGNAc) 0 = gANC3E (Mall) 4 =FUCOSE (Fuc) --.... ,-1 (57) : Factor VII glycoproteins having glycosylation patterns that render them suitable for therapeutic indications such as 0 postpartum hemorrhage requiring short half -life and rapid and high clearance are disclosed with related methods of making and using, \" and formulations. C [Continued on next page] WO 2018/052827 Al OII TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393930P | 2016-09-13 | 2016-09-13 | |
| PCT/US2017/050887 WO2018052827A1 (en) | 2016-09-13 | 2017-09-11 | Factor viia glycoforms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901989VA true SG11201901989VA (en) | 2019-04-29 |
Family
ID=61620165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901989VA SG11201901989VA (en) | 2016-09-13 | 2017-09-11 | Factor viia glycoforms |
| SG10202112746PA SG10202112746PA (en) | 2016-09-13 | 2017-09-11 | Factor viia glycoforms |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202112746PA SG10202112746PA (en) | 2016-09-13 | 2017-09-11 | Factor viia glycoforms |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190211319A1 (en) |
| EP (1) | EP3512876B1 (en) |
| JP (1) | JP2019530672A (en) |
| KR (1) | KR20190045350A (en) |
| CN (1) | CN109963866A (en) |
| CA (1) | CA3036527A1 (en) |
| DK (1) | DK3512876T3 (en) |
| ES (1) | ES2902645T3 (en) |
| MX (1) | MX2019002734A (en) |
| PL (1) | PL3512876T3 (en) |
| SG (2) | SG11201901989VA (en) |
| WO (1) | WO2018052827A1 (en) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10022092A1 (en) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilized protein preparation and process for its preparation |
| CA2557725C (en) | 2004-02-13 | 2015-06-30 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
| WO2005123916A2 (en) | 2004-06-21 | 2005-12-29 | Novo Nordisk Health Care Ag | Glycosylation-disrupted factor vii variants |
| PL1841863T3 (en) | 2005-01-14 | 2011-05-31 | Bayer Healthcare Llc | Method for purification of factor vii |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| CN101646775B (en) * | 2006-12-28 | 2016-08-24 | 森托科尔奥索生物科技公司 | For producing method and the carrier of asialylated immunoglobulins |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| SG190260A1 (en) * | 2011-01-06 | 2013-06-28 | Univ Johns Hopkins | Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells |
| WO2013017555A1 (en) * | 2011-08-01 | 2013-02-07 | Lfb-Biotechnologies | Factor vii compositions with specific glycosylation for controlled half-life |
| DK3165232T3 (en) * | 2012-12-24 | 2019-09-16 | Coagulant Therapeutics Corp | FACTOR VII POLYPEPTIDES WITH SHORT-TERM EFFECT |
-
2017
- 2017-09-11 EP EP17851361.0A patent/EP3512876B1/en active Active
- 2017-09-11 ES ES17851361T patent/ES2902645T3/en active Active
- 2017-09-11 WO PCT/US2017/050887 patent/WO2018052827A1/en unknown
- 2017-09-11 JP JP2019513825A patent/JP2019530672A/en active Pending
- 2017-09-11 SG SG11201901989VA patent/SG11201901989VA/en unknown
- 2017-09-11 KR KR1020197010418A patent/KR20190045350A/en active IP Right Grant
- 2017-09-11 CN CN201780069817.6A patent/CN109963866A/en active Pending
- 2017-09-11 PL PL17851361T patent/PL3512876T3/en unknown
- 2017-09-11 MX MX2019002734A patent/MX2019002734A/en unknown
- 2017-09-11 DK DK17851361.0T patent/DK3512876T3/en active
- 2017-09-11 CA CA3036527A patent/CA3036527A1/en not_active Abandoned
- 2017-09-11 SG SG10202112746PA patent/SG10202112746PA/en unknown
- 2017-09-11 US US16/332,289 patent/US20190211319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2902645T3 (en) | 2022-03-29 |
| PL3512876T3 (en) | 2022-02-14 |
| KR20190045350A (en) | 2019-05-02 |
| EP3512876A4 (en) | 2020-04-22 |
| CA3036527A1 (en) | 2018-03-22 |
| WO2018052827A1 (en) | 2018-03-22 |
| US20190211319A1 (en) | 2019-07-11 |
| EP3512876A1 (en) | 2019-07-24 |
| DK3512876T3 (en) | 2021-11-15 |
| MX2019002734A (en) | 2019-05-27 |
| EP3512876B1 (en) | 2021-10-27 |
| SG10202112746PA (en) | 2021-12-30 |
| CN109963866A (en) | 2019-07-02 |
| JP2019530672A (en) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201808524QA (en) | Devices, systems and methods for inhibiting invasion and metastases of cancer | |
| SG11201811035TA (en) | Core-composite shell microcapsules | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201903060XA (en) | Metallocene catalysts, catalyst systems, and methods for using the same | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201807015YA (en) | Method of assembling an electronic subassembly for a personal care product | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201811251RA (en) | Multi-chamber deposition equipment for solid free form fabrication | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201809749VA (en) | Computer systems and methods for implementing in-memory data structures | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201901188VA (en) | Metal powder feedstocks for additive manufacturing, and system and methods for producing the same | |
| SG11201901646VA (en) | Air lubrication system with a wave deflector for a vessel | |
| SG11201806855WA (en) | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |